HEMOSTASIS PROFILE AND LIPID-METABOLISM WITH LONG-INTERVAL USE OF A DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVE

被引:29
作者
CACHRIMANIDOU, AC
HELLBERG, D
NILSSON, S
VONSCHOULZ, B
CRONA, N
SIEGBAHN, A
机构
[1] KAROLINSKA HOSP,DEPT OBSTET & GYNECOL,S-10401 STOCKHOLM,SWEDEN
[2] SAHLGRENS UNIV HOSP,DEPT OBSTET & GYNECOL,GOTHENBURG,SWEDEN
[3] UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN
关键词
LONG-INTERVAL OC REGIMEN; DESOGESTREL; LIPOPROTEIN PATTERN; HEMOSTASIS; HORMONE-BINDING GLOBULINS;
D O I
10.1016/0010-7824(94)90051-5
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Thirty healthy women, aged 18 to 37, were randomly allocated to treatment with a desogestrel-containing oral contraceptive, with 20 women using a nine-week on, one-week off regimen, and 10 women using the traditional regimen. At 0, 3 and 12 months, blood samples were drawn for liver proteins, lipoproteins and hemostatic variables. No significant changes were observed between the two regimens. Sex hormone binding globulin (SHBG) and corticosteroid binding globulin (CBG, transcortin) were increased two- to four-fold, as a measure of estrogenicity. Minimal changes occurred within the lipoprotein cholesterol fractions, whereas there were some increases within the lipoprotein triglyceride fractions. Among the hemostatic variables, there were significant increases of fibrinogen, factor VII and thrombin/antithrombin III (TAT) complex. The coagulation inhibitors, antithrombin III, protein C and protein S, were essentially unchanged. A decrease of both tissue plasminogen activator antigen (t-PA) and tissue plasminogen activator inhibitor activity (PAI activity) of the fibrinolytic system was observed. A nine-week regimen does not seem to alter lipid metabolism and coagulation more than a three-week regimen.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 33 条
[1]
ORAL-CONTRACEPTIVES, LIPOPROTEINS, AND ATHEROSCLEROSIS [J].
ADAMS, MR ;
CLARKSON, TB ;
SHIVELY, CA ;
PARKS, JS ;
KAPLAN, JR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (04) :1388-1393
[2]
INCREASED RISK OF VENOUS THROMBOSIS IN CARRIERS OF HEREDITARY PROTEIN-C DEFICIENCY DEFECT [J].
ALLAART, CF ;
POORT, SR ;
ROSENDAAL, FR ;
REITSMA, PH ;
BERTINA, RM ;
BRIET, E .
LANCET, 1993, 341 (8838) :134-138
[3]
BOTTIGER LE, 1980, LANCET, V1, P1097
[4]
LONG-INTERVAL TREATMENT REGIMEN WITH A DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVE [J].
CACHRIMANIDOU, AC ;
HELLBERG, D ;
NILSSON, S ;
WALDENSTROM, U ;
OLSSON, SE ;
SIKSTROM, B .
CONTRACEPTION, 1993, 48 (03) :205-216
[5]
HEMOSTASIS PROFILE IN WOMEN TAKING LOW-DOSE ORAL-CONTRACEPTIVES [J].
DAVID, JL ;
GASPARD, UJ ;
GILLAIN, D ;
RASKINET, R ;
LEPOT, MR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (01) :420-423
[6]
ELSTEIN M, 1989, Advances in Contraception, V5, P237, DOI 10.1007/BF01890896
[7]
ENGEL HJ, 1983, EUR HEART J, V4, P1
[8]
ENGEL HJ, 1977, BRIT HEART J, V39, P477
[9]
ORAL-CONTRACEPTIVES, LIPIDS AND CARDIOVASCULAR-DISEASE [J].
FOTHERBY, K .
CONTRACEPTION, 1985, 31 (04) :367-394
[10]
GERSTMAN GG, 1991, AM J EPIDEMIOL, V133, P327